The company is responsible for much of the interior work in both private and public jets. Due to the strong backlog for plane manufacturers, shares of BEAV have been "up, up, up!" he exclaimed.
B/E Aerospace cancelled its analyst meeting originally scheduled for today, announcing that is exploring a potential sale, merger or split up, Cramer added. Although some analysts are calling shares of BEAV overvalued, Cramer disagreed, arguing, "This company is worth a great deal."
So who would buy the company?Rockwell Collins (COL) would be a possible merger candidate, he said, but not Honeywell International (HON). Turning to Pfizer (PFE), Cramer was not impressed by its earnings results. He added that AstraZeneca (AZN) -- the company Pfizer wants to buy -- does not have as strong a cancer pipeline as initially thought. He concluded that Merck (MRK) has a more "exciting story" than Pfizer, especially with its consumer products division.
-- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts